Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03337477 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT03337477 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 70 participants.
The verdict
NCT03337477, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The study is designed to determine if ZS 10g administered up to three times over 10h added to insulin and glucose in patients presenting with hyperkalemia will prove tolerable and efficacious. Patients will receive ZS or Placebo on top of standard of care treatment with insulin and glucose.
Interventions
- DRUG Placebo
- DRUG Insulin
- DRUG Glucose
- DRUG Sodium Zirconium Cyclosilicate(ZS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2018-02-13 |
| Est. Completion | 2018-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03337477
The ClinicalTrials.gov registry entry for NCT03337477 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03337477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03337477 about?
NCT03337477 is a clinical study titled "A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8". The study is designed to determine if ZS 10g administered up to three times over 10h added to insulin and glucose in patients presenting with hyperkalemia will prove tolerable and efficacious. Patients will receive ZS or Placebo on top of standard of care treatment with insulin and glucose.
What is the current status of trial NCT03337477?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2018-02-13. Estimated completion is 2018-12-21.
What interventions are being tested in trial NCT03337477?
The interventions under investigation include: Placebo (DRUG), Insulin (DRUG), Glucose (DRUG), Sodium Zirconium Cyclosilicate(ZS) (DRUG).
Who is sponsoring clinical trial NCT03337477?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.